Article Information
- Received March 18, 2013
- Revision received May 6, 2013
- Accepted May 6, 2013
- First published June 12, 2013.
- Version of record published June 12, 2013.
Author Information
Author contributions
Author contributions: S.E., J.J., F.J., K.K., S.G., S.K., and B.-M.S. designed research; S.E., J.J., F.J., S.G., A.-C.R., K.E., S.B., P.A., and A.-L.B. performed research; S.E., J.J., F.J., and A.S. analyzed data; S.E., J.J., F.J., A.S., K.K., C.N., and J.F. wrote the paper.
Disclosures
- Received March 18, 2013.
- Revision received May 6, 2013.
- Accepted May 6, 2013.
This work was founded by AstraZeneca and all authors were at the time of the work employees of AstraZeneca. A special thanks to Daniel Bergström, Ann Staflund, and Anette Stålebring-Löwstedt for excellent animal husbandry and technical assistant. Kerstin Nilsson is acknowledged for statistical support and Anna Bogstedt for Aβ measurements. Special thanks also to Eva Spennare for determining the fraction unbound in brain by the brain slice method and Jenny Johansson for measuring the plasma protein binding. Per-Olof Markgren and Karin Kaspersson are acknowledged for additional affinity measurements and for critical reading of this manuscript.
- Correspondence should be addressed to Susanna Eketjäll, AstraZeneca Translational Sciences Centre, Science for Life Laboratory, S-171 65 Solna, Sweden. Susanna.Eketjall{at}astrazeneca.com
Statistics from Altmetric.com
Article usage
In this issue
